Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: In vitro and in vivo activity of miR-92a–Locked Nucleic Acid (LNA)–Inhibitor against endometrial cancer

Authors: Anna Torres, Joanna Kozak, Agnieszka Korolczuk, Paulina Wdowiak, Ewa Domańska-Glonek, Ryszard Maciejewski, Kamil Torres

Published in: BMC Cancer | Issue 1/2016

Login to get access

Excerpt

After the publication of the article [1], the authors realised it contained an error with the Methods section. The following paragraph should be deleted from the original article: …
Literature
1.
Metadata
Title
Erratum to: In vitro and in vivo activity of miR-92a–Locked Nucleic Acid (LNA)–Inhibitor against endometrial cancer
Authors
Anna Torres
Joanna Kozak
Agnieszka Korolczuk
Paulina Wdowiak
Ewa Domańska-Glonek
Ryszard Maciejewski
Kamil Torres
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2971-0

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Validation of the flemish CARES, a quality of life and needs assessment tool for cancer care

Research article

Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer

Erratum

Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

Study protocol

Effectiveness of community-based football compared to usual care in men with prostate cancer: Protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate Community Trial)

Research article

Predicting general and cancer-related distress in women with newly diagnosed breast cancer

Research article

Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits